03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
13:25 , Feb 8, 2019 |  BioCentury  |  Emerging Company Profile

Palleon: Sweeter checkpoints

With two platforms targeting glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc. aims to treat cancer by removing the brakes on a class of checkpoints...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
18:49 , Jul 13, 2018 |  BioCentury  |  Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
19:26 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Pfizer's CD33-positive AML drug Mylotarg approved in Europe

Pfizer Inc. (NYSE:PFE) said the European Commission approved Mylotarg gemtuzumab ozogamicin for treatment-naïve, de novo, CD33-positive acute myelogenous leukemia in patients ages 15 and older. The pharma said the drug is the only AML therapy...
20:50 , Apr 23, 2018 |  BC Extra  |  Company News

Pfizer's CD33-positive AML drug approved in Europe

Pfizer Inc. (NYSE:PFE) said the European Commission approved Mylotarg gemtuzumab ozogamicin for treatment-naïve, de novo , CD33-positive acute myelogenous leukemia in patients ages 15 and older. The pharma said the drug is the only AML...
00:31 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

CHMP backs approval for Pfizer's AML triple combo

EMA's CHMP recommended approval of Mylotarg gemtuzumab ozogamicin from Pfizer Inc. (NYSE:PFE) in combination with daunorubicin and cytarabine to treat previously untreated, CD33-positive acute myelogenous leukemia (AML), except acute promyelocytic leukemia (APL), in patients ages...
00:15 , Feb 24, 2018 |  BC Extra  |  Company News

CHMP backs approval of Mylotarg, Alpivab, Kineret

EMA's CHMP announced a spate of opinions Friday, including positive recommendations for Mylotarg gemtuzumab ozogamicin, Alpivab peramivir and Kineret anakinra, as well as the expected negative opinion for Nerlynx neratinib. The committee recommended approval of...
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...